These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35031092)

  • 1. Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis.
    Keeney E; Thom H; Turner E; Martin RM; Morley J; Sanghera S
    Value Health; 2022 Jan; 25(1):133-146. PubMed ID: 35031092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
    Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
    Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
    de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
    Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    Faria R; Soares MO; Spackman E; Ahmed HU; Brown LC; Kaplan R; Emberton M; Sculpher MJ
    Eur Urol; 2018 Jan; 73(1):23-30. PubMed ID: 28935163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.
    Gulati R; Jiao B; Al-Faouri R; Sharma V; Kaul S; Fleishman A; Wymer K; Boorjian SA; Olumi AF; Etzioni R; Gershman B
    Ann Intern Med; 2024 Jul; 177(7):871-881. PubMed ID: 38830219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.
    Nicholson A; Mahon J; Boland A; Beale S; Dwan K; Fleeman N; Hockenhull J; Dundar Y
    Health Technol Assess; 2015 Oct; 19(87):i-xxxi, 1-191. PubMed ID: 26507078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.
    Stinton C; Jordan M; Fraser H; Auguste P; Court R; Al-Khudairy L; Madan J; Grammatopoulos D; Taylor-Phillips S
    Health Technol Assess; 2021 Jun; 25(42):1-216. PubMed ID: 34169821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
    Getaneh AM; Heijnsdijk EA; de Koning HJ
    Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
    Sanghera S; Coast J; Martin RM; Donovan JL; Mohiuddin S
    BMC Cancer; 2018 Jan; 18(1):84. PubMed ID: 29347916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy Versus Systematic Transrectal Ultrasound-Guided Biopsy for Prostate Cancer Diagnosis: A Systematic Review.
    Rezapour A; Alipour V; Moradi N; Arabloo J
    Value Health Reg Issues; 2022 Jul; 30():31-38. PubMed ID: 35042021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
    Bresnahan R; Duarte R; Mahon J; Beale S; Chaplin M; Bhattacharyya D; Houten R; Edwards K; Nevitt S; Maden M; Boland A
    Health Technol Assess; 2023 Jul; 27(10):1-115. PubMed ID: 37839810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
    Heijnsdijk EA; Denham D; de Koning HJ
    Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
    Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
    J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
    Keeney E; Sanghera S; Martin RM; Gulati R; Wiklund F; Walsh EI; Donovan JL; Hamdy F; Neal DE; Lane JA; Turner EL; Thom H; Clements MS
    Pharmacoeconomics; 2022 Dec; 40(12):1207-1220. PubMed ID: 36201131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.